Androgens induce divergent proliferative responses in human breast cancer cell lines - PubMed (original) (raw)
Androgens induce divergent proliferative responses in human breast cancer cell lines
S N Birrell et al. J Steroid Biochem Mol Biol. 1995 May.
Abstract
Although the majority of primary human breast cancers express the androgen receptor (AR), the role of androgens in breast cancer growth and progression is poorly understood. We have investigated the effects of the naturally occurring androgen, dihydrotestosterone (DHT), and a synthetic non-metabolizable androgen, mibolerone, on the proliferation of six human breast cancer cell lines. The anti-proliferative and proliferative effects of androgens were only observed in cell lines that expressed the AR. Two of the AR-positive cell lines, T47-D and ZR-75-1 were growth inhibited in the presence of either DHT or mibolerone, while the proliferation of MCF-7 and MDA-MB-453 cells was increased by both androgens. Co-incubation of cultures with 1 nM DHT and a 100-fold excess of the androgen receptor antagonist, hydroxyflutamide, resulted in reversal of both inhibitory and stimulatory effects of DHT on T47-D, MCF-7 and MDA-MB-453 cell proliferation, indicating that DHT action is mediated by the AR in these lines. Hydroxyflutamide only partially reversed the DHT-induced growth inhibition of ZR-75-1 cultures, which suggests that growth inhibition of these cells may be mediated by non-AR pathways of DHT (or DHT metabolite) action. Mibolerone action on breast cancer cell growth was similar to that of DHT, with the exception that growth stimulation of MCF-7 and MDA-MB-453 cells was only partially reversed in the presence of a 100-fold excess of hydroxyflutamide. Anandron, another androgen receptor antagonist, was able to reverse all inhibitory and stimulatory actions of the androgens. AR antisense oligonucleotides reduced the level of immunoreactive AR expression in MDA-MB-453 and ZR-75-1 cells by more than 60%, but only reversed the growth inhibitory action of mibolerone in ZR-75-1 cultures. The results suggest that androgen action in breast cancer cell lines may not be solely mediated by binding of androgen to the AR. For example, metabolites of DHT with oestrogenic activity, or androgen binding to receptors other than the AR, may explain the divergent responses to androgens observed in different breast cancer cell lines.
Similar articles
- Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells.
Bentel JM, Birrell SN, Pickering MA, Holds DJ, Horsfall DJ, Tilley WD. Bentel JM, et al. Mol Cell Endocrinol. 1999 Aug 20;154(1-2):11-20. doi: 10.1016/s0303-7207(99)00109-4. Mol Cell Endocrinol. 1999. PMID: 10509795 - Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors.
Cops EJ, Bianco-Miotto T, Moore NL, Clarke CL, Birrell SN, Butler LM, Tilley WD. Cops EJ, et al. J Steroid Biochem Mol Biol. 2008 Jun;110(3-5):236-43. doi: 10.1016/j.jsbmb.2007.10.014. Epub 2008 Apr 20. J Steroid Biochem Mol Biol. 2008. PMID: 18515094 - Development of two androgen receptor assays using adenoviral transduction of MMTV-luc reporter and/or hAR for endocrine screening.
Hartig PC, Bobseine KL, Britt BH, Cardon MC, Lambright CR, Wilson VS, Gray LE Jr. Hartig PC, et al. Toxicol Sci. 2002 Mar;66(1):82-90. doi: 10.1093/toxsci/66.1.82. Toxicol Sci. 2002. PMID: 11861975 - Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids.
Hackenberg R, Schulz KD. Hackenberg R, et al. J Steroid Biochem Mol Biol. 1996 Jan;56(1-6 Spec No):113-7. doi: 10.1016/0960-0760(95)00228-6. J Steroid Biochem Mol Biol. 1996. PMID: 8603031 Review. - Role of the androgen receptor in human breast cancer.
Birrell SN, Hall RE, Tilley WD. Birrell SN, et al. J Mammary Gland Biol Neoplasia. 1998 Jan;3(1):95-103. doi: 10.1023/a:1018730519839. J Mammary Gland Biol Neoplasia. 1998. PMID: 10819508 Review.
Cited by
- The androgen receptor interacts with GATA3 to transcriptionally regulate a luminal epithelial cell phenotype in breast cancer.
Hosseinzadeh L, Kikhtyak Z, Laven-Law G, Pederson SM, Puiu CG, D'Santos CS, Lim E, Carroll JS, Tilley WD, Dwyer AR, Hickey TE. Hosseinzadeh L, et al. Genome Biol. 2024 Feb 5;25(1):44. doi: 10.1186/s13059-023-03161-y. Genome Biol. 2024. PMID: 38317241 Free PMC article. - Integrins and Actions of Androgen in Breast Cancer.
Tsai CC, Yang YSH, Chen YF, Huang LY, Yang YN, Lee SY, Wang WL, Lee HL, Whang-Peng J, Lin HY, Wang K. Tsai CC, et al. Cells. 2023 Aug 22;12(17):2126. doi: 10.3390/cells12172126. Cells. 2023. PMID: 37681860 Free PMC article. Review. - Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer.
Leo J, Dondossola E, Basham KJ, Wilson NR, Alhalabi O, Gao J, Kurnit KC, White MG, McQuade JL, Westin SN, Wellberg EA, Frigo DE. Leo J, et al. Endocrinology. 2023 Apr 17;164(6):bqad071. doi: 10.1210/endocr/bqad071. Endocrinology. 2023. PMID: 37154098 Free PMC article. Review. - Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor-Positive Breast Cancer.
Wei L, Gao H, Yu J, Zhang H, Nguyen TTL, Gu Y, Passow MR, Carter JM, Qin B, Boughey JC, Goetz MP, Weinshilboum RM, Ingle JN, Wang L. Wei L, et al. Cancer Res. 2023 Feb 3;83(3):456-470. doi: 10.1158/0008-5472.CAN-22-1016. Cancer Res. 2023. PMID: 36469363 Free PMC article. - Association of androgen receptor expression with glucose metabolic features in triple-negative breast cancer.
Lee R, Lee HB, Paeng JC, Choi H, Whi W, Han W, Seok JW, Kang KW, Cheon GJ. Lee R, et al. PLoS One. 2022 Sep 30;17(9):e0275279. doi: 10.1371/journal.pone.0275279. eCollection 2022. PLoS One. 2022. PMID: 36178912 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous